Title :

Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.

Author(s) :

Lafon-Desmurs, Barthelemy [Auteur]
Centre Hospitalier Tourcoing
Gachet, Benoit [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Hennart, Benjamin [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Valentin, Benjamin [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Roosen, Gabrielle [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Degrendel, Maxime [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Loiez, Caroline [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Beltrand, Eric [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
D'Elia, Piervito [Auteur]
Centre Hospitalier Tourcoing
Migaud, Henri [Auteur]
Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
Robineau, Olivier [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Senneville, Eric [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]

Journal title :

European Journal of Clinical Microbiology and Infectious Diseases

Abbreviated title :

Eur J Clin Microbiol Infect Dis

Volume number :

43

Pages :

1475–1480

Publisher :

Springer Nature

Publication date :

2024-06-01

ISSN :

1435-4373

English keyword(s) :

Dalbavancin
Suppressive therapy
Prosthetic joint infection
Vascular graft infection
Dosage

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with ...
Show more >Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2–7). Median time between two reinjections was 57 days (IQR 28–82). Dalbavancin plasma concentrations were above 4 mg/L for 97.9% of dosages (93/95) and above 8 mg/L for 85% (81/95). These results support the use of dalbavancin SAT for implant-related infections.Show less >

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille
Institut Pasteur de Lille

Collections :

• IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483

Submission date :

2025-04-09T21:14:10Z
2025-04-23T09:53:22Z